Private Equity-Backed Lantheus Faces a Make-Or-Break Year

NEW YORK ( TheDeal) -- Although it has solved its supply chain issues and installed a growth strategy, private equity-backed Lantheus Medical Imaging faces a make-or-break year when it comes to stopping a decline in sales and getting itself back in the good graces of the rating agencies.

"I think 2014 will be a critical year," said Moody's Investors Service analyst Michael Levesque, who has a Caa3 negative rating on the medical device company. "Either [Lantheus] turns around after the resolution of the supply chain issues or they continue to struggle and liquidity weakens."

Read more from:

If you liked this article you might like

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

Bristol-Myers 'Is Back' and Could Soar Another 14%

Bristol-Myers 'Is Back' and Could Soar Another 14%

These Were the 3 Hottest Stories on Wall Street Thursday

These Were the 3 Hottest Stories on Wall Street Thursday

Rock and Roll: Bristol-Myers Squibb Is Breaking Out

Rock and Roll: Bristol-Myers Squibb Is Breaking Out

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains